Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0517 • ACR Convergence 2022
Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus
Santiago Arciniegas¹, Sarah Mossad², Tala El Tal³, Victoria Lishak⁴, Stephanie Fevrier⁵, Ibrahim Mohamed⁶, Joanna Law², Lawrence Ng², Paris Moaf², Helen Branson², Adrienne Davis², Linda Hiraki⁷, Deborah Levy⁸, ashley Danguecan², George Ibrahim⁵ and Andrea Knight³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…
Abstract Number: 0638 • ACR Convergence 2022
Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
Maxime DUBOIS¹, Renaud FELTEN¹ and jacques-eric gottenberg², ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Despite improvements in the understanding of the pathogenesis of Systemic Lupus Erythematosus (SLE), very few new treatments have proven their effectiveness. Drug development is…
Abstract Number: 0658 • ACR Convergence 2022
Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
Zachary Cutts¹, Sarah Patterson², Lenka Maliskova¹, Chun Ye², Maria Dall'Era³, Jinoos Yazdany⁴, Lindsey Criswell⁵, Charles Langelier⁶, Marina Sirota⁷ and Cristina M Lanata⁸, ¹University of California, San Francisco, San Francisco, ²University of California, San Francisco, San Francisco, CA, ³University of California, Division of Rheumatology, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵National Human Genome Research Institute, NIH, Bethesda, MD, ⁶UCSF, San Francisco, ⁷UCSF, SF, ⁸NIH/NHGRI, Washington, DC
Background/Purpose: Human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs) make up 5-8% and 21% of the human genome, respectively. Their expression may contribute…
Abstract Number: 0746 • ACR Convergence 2022
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
Ho SO¹, Evelyn Chow², Isaac Cheng¹, Xerox Lau², Tena Li¹, Cheuk Chun Szeto² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
Abstract Number: 0962 • ACR Convergence 2022
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Megan Clowse¹, Jim Oates², Katie Kirchoff², April Barnado³, Saira Sheikh⁴, Leslie Crofford³ and Amanda Eudy⁵, ¹Duke University, Durham, NC, ²Medical University of South Carolina, Charleston, SC, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
Abstract Number: 0983 • ACR Convergence 2022
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jake Altier, Fedelis Mutiso, Paul Nietert, Sheldon Litwin and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…
Abstract Number: 1000 • ACR Convergence 2022
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
J. Michelle Kahlenberg¹, Iñaki Sanz², Chun Wu³, Sarah Hu³, Jin Hyang Kim³, Shalabh Singhal³ and Ian M. Catlett³, ¹University of Michigan, Ann Arbor, MI, ²Emory University, Atlanta, GA, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib (DEUC) has a…
Abstract Number: 1192 • ACR Convergence 2022
Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample
Jiayi Zheng¹, Ruoning Ni², Guangchen Zou³, Yuhao Zeng⁴, Naeem ijaz¹ and Yani Zhang⁵, ¹The Wright Center for Graduate Medical Education, Scranton, PA, ²Ascension Saint Agnes Hospital, Iowa City, IA, ³Danbury Hospital, Danbury, CT, ⁴Cleveland Clinic Akron General, Akron, OH, ⁵MedStar Union Memorial Hospital, Baltimore, MD
Background/Purpose: Celiac disease is an autoimmune disease characterized by the immunologic reaction to gluten by lymphocytes. Although recent studies suggest an association between celiac disease…
Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
Abstract Number: 1445 • ACR Convergence 2022
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
Pankti Mehta¹, Akansha Srivastava², Amita Aggarwal², Liza Rajasekhar³, Vineetha Shobha⁴, Chengappa Kavadichanda⁵, ASHISH JACOB MATHEW⁶, Parasar Ghosh⁷, Bidyut Das⁸, Avinash Jain⁹, Ranjan Gupta¹⁰ and Manish Rathi¹¹, ¹King George's Medical University, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴St. John’s Medical College Hospital, Bangalore, India, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶Christian Medical College, Vellore, Vellore, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰All India Institute of Medical Sciences, New Delhi, India, ¹¹PGIMER Chandigarh, Chandigarh, India
Background/Purpose: Gastrointestinal (GI) manifestations of Systemic Lupus Erythematosus (SLE) although rare are often severe. These are difficult to directly attribute to SLE as they can…
Abstract Number: 1462 • ACR Convergence 2022
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Samar Soliman¹, Samantha Stanley², Kamala Vanarsa², Faten Ismail³, Chi Chiu Mok⁴ and Chandra mohan⁵, ¹Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, ²Department of Biomedical Engineering, University of Houston, Houston, TX, ³Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, ⁴Tuen Mun Hospital, Hong Kong, China, ⁵University of Houston, Houston, TX
Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
Abstract Number: 1481 • ACR Convergence 2022
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
Sarah Lieber¹, Musarrat Nahid², Iris Navarro-Millan², Mangala Rajan², Sebastian Sattui³, Robyn Lipschultz¹, M. Carrington Reid² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with increased risk of dementia relative to age-matched comparators without systemic rheumatic disease (SRD) in non-US-based samples…
Abstract Number: 1656 • ACR Convergence 2022
Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial
Anca Askanase¹, Ouali Berkani², clélia Cahuzac³, peter Cornelisse³, David D'Cruz⁴, Kenneth Kalunian⁵, Joan Merrill⁶, Marilia Pozzobon³ and Sandra Navarra⁷, ¹Columbia University Medical Center, New York, NY, ²IDORSIA, Allschwil, Switzerland, ³Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷University of Santo Tomas, Manila, Philippines
Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs. In an SLE proof-of-concept study, cenerimod—a potent, selective S1P receptor modulator—reduced lymphocyte count and disease activity…
Abstract Number: 1720 • ACR Convergence 2022
FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus
Ritu Bohat¹, Chunyu Xu¹, Xiaofang Liang¹, Yanping Chen¹, Ningbo Zheng¹, Roshni Jaffery¹, Ashley Guerrero¹, Nicholas Egan¹, John Hicks², Chandra mohan¹ and Weiyi Peng¹, ¹University of Houston, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Sle1 and FASlpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus (SLE) by altering the FAS/FASL pathway and adaptive…
Abstract Number: 2052 • ACR Convergence 2022
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar¹, Forsythe Hannah², Louis Saravolatz³ and Susanna Szpunar⁴, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].